Fluticasone furoate (FF)
24-hour anti-inflammatory action in vitro with low systemic exposure2-4
Prescribing information links can be found at the bottom of this page
*The clinical significance of in vitro data is not known. Systemic exposure assessed when FF administered as FF/VI by inhalation in patients with COPD.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2021 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with
PM-GB-FVU-WCNT-210007 | June 2021